Verification evidence is still being completed.
PDF / print export
Sobi
Stockholm, Sweden
- Verified lead
- Guido Oelkers
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Rare Disease Therapeutics and Technical Operations
- Review cycle
- May 2026
- Full address
- Norra Stationsgatan 93A, 113 64 Stockholm, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Sobi executive committee page confirming Guido Oelkers as CEO.
- Editorial note
- Sobi is published as a Stockholm headquarters and technical-operations anchor. The directory treats this as a current operating-control node rather than a live internal GMP production plant after the company's 2024 manufacturing exit for ReFacto.
Rare Disease Therapeutics and Technical Operations
Quality and pharmacovigilance oversight, Commercial rare-disease operations
Sobi is published as a Stockholm headquarters and technical-operations anchor. The directory treats this as a current operating-control node rather than a live internal GMP production plant after the company's 2024 manufacturing exit for ReFacto.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Stockholm, Sweden
Sobi
Rare Disease Therapeutics and Technical Operations · Global rare-disease operations
Verified 14 Mar 2026 · 3 sources
Commercial
The directory treats this as a current operating-control node rather than a live internal GMP production plant after the company's 2024 manufacturing exit for ReFacto.
Contact & location
- Website
- sobi.com
- Company page
- Lead
- Guido Oelkers (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Global rare-disease operations
- Capabilities
- Rare Disease Portfolio Management · Technical Operations Oversight · Medical and Market Access Operations
- Founded
- 2010
- Headcount
- 1001-5000
Clinical profileSTATUS: VERIFIED MARCH 2026
Guido Oelkers
Chief Executive Officer
Full addressNorra Stationsgatan 93A, 113 64 Stockholm, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Sobi contacts page listing the Stockholm head office visiting address at Norra Stationsgatan 93A.
Open sourceGlobal rare-disease operations
Stockholm, Sweden. Rare Disease Therapeutics and Technical Operations. Review completed on 14 Mar 2026.
EMA and Swedish pharmaceutical oversight
Quality and pharmacovigilance oversight, Commercial rare-disease operations
Rare Disease Therapeutics and Technical Operations
Sobi is published as a Stockholm headquarters and technical-operations anchor. The directory treats this as a current operating-control node rather than a live internal GMP production plant after the company's 2024 manufacturing exit for ReFacto.
Editorial note
Sobi is published as a Stockholm headquarters and technical-operations anchor. The directory treats this as a current operating-control node rather than a live internal GMP production plant after the company's 2024 manufacturing exit for ReFacto.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Rare Disease Portfolio Management
Technical Operations Oversight
Medical and Market Access Operations
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Global technical operations hub
Medical affairs systems
Commercial and pharmacovigilance platforms
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Trust review remains in progress.
FAQ
Frequently asked questions
- Where is Sobi located?
- Sobi operates from Norra Stationsgatan 93A, 113 64 Stockholm, Sweden, Stockholm, Sweden.
- Who runs Sobi?
- Sobi is led by Guido Oelkers, Chief Executive Officer. Verified 14 Mar 2026.
- What does Sobi do?
- The directory treats this as a current operating-control node rather than a live internal GMP production plant after the company's 2024 manufacturing exit for ReFacto. Core capabilities: Rare Disease Portfolio Management, Technical Operations Oversight, Medical and Market Access Operations.
Editorial context
Related technical briefs
Briefs that name Stockholm as a covered market or city.